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In this issue of the Journal, Gaita et al. (1) report ﬁndings
from 270 patients, of whom 180 had atrial ﬁbrillation and
90 with similar demographic and clinical characteristics did
not have atrial ﬁbrillation. All were free of clinical stroke at
the time of the study, and all underwent brain magnetic
resonance imaging (MRI). Silent cerebral ischemia (SCI) was
deﬁned as a focal, sharply demarcated area on MRI of hyper-
intensity on T2-weighted ﬂuid-attenuated inversion recovery
or isointensity on T1-weighted imaging. The numbers of SCI
lesions, and the areas of the brain in which they were observed,
were determined. A standardized measure of cognitive func-
tion was also obtained. Gaita et al. found a substantially higher
prevalence of SCI in those with atrial ﬁbrillation compared
with those in sinus rhythm, with an approximately 3-fold
greater number of areas of SCI in those with atrial ﬁbrillation.
Cognitive performance was worse in those with atrial ﬁbrilla-
tion. Two other analyses were also performed. Gaita et al. (1)
attempted to distinguish between patients with persistent
and those with paroxysmal atrial ﬁbrillation, and they
attempted to relate the MRI ﬁndings to cognitive perfor-
mance. We comment below on each of these ﬁndings.
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Silent cerebral ischemic scars may be caused by small
hemorrhagic infarctions, related in part to hypertension, or
by emboli, which may originate in the ﬁbrillating atria or
from plaque in the cerebrovascular circulation (2). Ezekowitz
et al. (3) reported in 1995 that 14.7% of 516 patients with
nonrheumatic atrial ﬁbrillation had silent ischemic infarcts
on computed tomography, a less sensitive modality than
MRI. There were no controls in that study. Kobayashi et al.*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From yDepartment of Medicine, Columbia University Medical Center, New York,
New York; and the zDepartment of Epidemiology, Columbia University Medical
Center, New York, New York. Drs. Shea and Di Tullio receive funding from the
National Institutes of Health.(4) reported in 2012 that patients with nonvalvular atrial
ﬁbrillation had a higher prevalence and greater number of
silent infarctions on MRI compared with a well-matched
control group. Neither of these reports provided data on
cognitive function. Thus, although the association of atrial
ﬁbrillation with stroke and transient ischemic attack is ﬁrmly
established, the study by Gaita et al. (1) adds important
conﬁrmatory data supporting an association with SCI. From
their imaging description and the example they show in
Figure 3, Gaita et al. (1) analyzed 1 of the manifestations of
silent brain ischemia, the presence of white matter hyper-
intensities (WMHs). Surprisingly, they did not report
separate results on another less common manifestation of
ischemia, namely, the presence of silent brain infarcts (SBI).
SBIs, which are focal lesions seen on both computed
tomography and MRI with similar intensity as cerebrospinal
ﬂuid (2), are present in 8% to 28% of patients in the general
population, with most of the difference in prevalence being
explained by age (2). While SBI and WMH are strongly
associated with each other and share common risk factors
(hypertension being the most important [2]) and probably
a common etiology (microvascular disease), they also appear
to have differences that go beyond their appearance on brain
imaging. In the Framingham Offspring study, both SBI and
WMH were independently associated with future stroke
occurrence, but only WMH was associated with death and
cognitive impairment, independent of vascular risk factors
and interim stroke (5). In the population-based Northern
Manhattan Study, increased physical activity was associated
with a decreased frequency of SBI but had no effect on
WMH volume (6). While SBI may be more representative
of a vascular etiology (whether microvascular or embolic),
WMH may more often have alternative explanations
(glyosis, demyelination, degenerative or inﬂammatory
changes, venous disease). An association of atrial ﬁbrillation
with SBI in the study of Gaita et al. (1) would have lent
stronger support to an embolic etiology of their ﬁndings, as
opposed to the possible combined effects of other mecha-
nisms that are also more frequent in atrial ﬁbrillation than in
sinus rhythm, such as increases in platelet activation,
thrombin generation, endothelial dysfunction, and inﬂam-
mation (7).
To distinguish persistent from paroxysmal atrial ﬁbrilla-
tion, Gaita et al. (1) used a clinical deﬁnition based on the
duration of 1 or more episodes lasting >7 days, on the basis
of data from the clinical history and medical record. Gaita
et al. (1) did not ﬁnd important differences between the
paroxysmal and persistent groups. Kobayashi et al. (4) also did
not ﬁnd differences for paroxysmal versus persistent atrial
ﬁbrillation. However, there are at least 2 serious challenges in
these analyses. First, it is difﬁcult to be sure of the validity of
the classiﬁcation, because atrial ﬁbrillation can be asymp-
tomatic. Second, some patients may have had paroxysmal
atrial ﬁbrillation before they had persistent atrial ﬁbrillation,
but it cannot be determined whether the SCIs observed on
MRI occurred during 1 phase or the other. Although
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1999inferences about paroxysmal versus persistent atrialﬁbrillation
on the basis of these data are weak, this limitation does not
affect the overall comparisons between those with atrial
ﬁbrillation versus controls.
Gaita et al. (1) also found measurably lower cognitive
performance in patients with atrial ﬁbrillation compared
with controls. This ﬁnding is consistent with a recent meta-
analysis of observational studies in which risk for cognitive
impairment in atrial ﬁbrillation was increased in patients
with and without stroke before the cognitive assessment (8).
As pointed out in that meta-analysis, methods for ascertain-
ing atrial ﬁbrillation and for measuring cognitive function are
not standardized across studies. In addition, Gaita et al. (1)
analyzed relationships between cognitive performance and
SCI density and location. These analyses suggest that
location may be more important than the number of lesions,
but the analyses were not based on a priori hypotheses, and
multiple test statistics were calculated. These ﬁndings should
therefore be regarded as exploratory. Nonetheless, the
observations are provocative. Gaita et al. (1) argue that the
ﬁnding of bilateral, clustered small lesions, predominantly
in the frontal lobes, namely, the pattern observed in the
present study, suggests thrombotic emboli arising in the
ﬁbrillating atria and can be distinguished from larger ipsilat-
eral (or monolateral) infarctions suggestive of atheroembolic
emboli originating in the cerebrovascular circulation. The
location of infarctions in the study of Kobayashi et al. (4) was
similar to that reported here. Given the aforementioned
uncertainty on the possibility of an embolic etiology of
WMH, the embolic signiﬁcance of the preferential
(“spotted”) pattern observed by Gaita et al. (1), although an
intriguing concept, remains in need of further research.
When analyzing the relationship between atrial ﬁbrilla-
tion and silent brain ischemia, the most important question
is whether prophylactic antithrombotic treatment may be
able to reduce the incidence of silent brain lesions as it has
been proved to do for clinical strokes. In the Gaita et al. (1)
study, an adequate measurement of patients’ exposure to
antithrombotic agents during the atrial ﬁbrillation episodes
was not available, preventing the investigators from drawing
any conclusions regarding treatment effect. This important
analysis will require appropriately designed and powered
prospective studies.
Finally, paroxysmal, often asymptomatic episodes of atrial
ﬁbrillation may be more frequent in the general populationthan previously thought, and their impact on the attributable
risk for stroke, SCI, or cognitive impairment is unknown.
The detection, monitoring, and characterization of atrial
ﬁbrillation in the population was set as 1 of the future health
policy goals by health organizations in the United States (9)
and in Europe (10). Devising feasible and cost-effective
strategies for detecting asymptomatic atrial ﬁbrillation in
subgroups, such as the elderly, that are at high risk for the
arrhythmia may become crucial to dealing with a condition
that, as the report by Gaita et al. (1) reminds us, can damage
the brain in more ways than one.
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